Your browser doesn't support javascript.
loading
No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic.
Schwaiger, Julia; Karbiener, Michael; Aberham, Claudia; Farcet, Maria R; Kreil, Thomas R.
Afiliação
  • Schwaiger J; Global Pathogen Safety, Baxter AG (part of Takeda), Vienna, Austria.
  • Karbiener M; Global Pathogen Safety, Baxter AG (part of Takeda), Vienna, Austria.
  • Aberham C; BioLife, Baxter AG (part of Takeda), Vienna, Austria.
  • Farcet MR; Global Pathogen Safety, Baxter AG (part of Takeda), Vienna, Austria.
  • Kreil TR; Global Pathogen Safety, Baxter AG (part of Takeda), Vienna, Austria.
J Infect Dis ; 222(12): 1960-1964, 2020 Nov 13.
Article em En | MEDLINE | ID: mdl-32941626
ABSTRACT
The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing, antibodies to the new species in humans is unclear. The question is particularly relevant for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 intravenous immunoglobulin preparations, produced from plasma collected in Europe and the United States, confirmed highly potent neutralization of a seasonal coronavirus; however, no cross-neutralization of the new SARS-CoV-2 was seen.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulinas Intravenosas / Anticorpos Neutralizantes / SARS-CoV-2 / Anticorpos Antivirais Limite: Humans País/Região como assunto: America do norte / Europa Idioma: En Revista: J Infect Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Áustria

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulinas Intravenosas / Anticorpos Neutralizantes / SARS-CoV-2 / Anticorpos Antivirais Limite: Humans País/Região como assunto: America do norte / Europa Idioma: En Revista: J Infect Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Áustria